Synergy Health plc Invests 18 Million GBP (US$30 Million) To Expand Global Applied Sterilisation Technology Capacity
Synergy Health, a leading provider of outsourced sterilisation and laboratory services to the healthcare industry, is investing £18 million (US$30M) to expand capacity in its Applied Sterilisation Technology (AST) division. The expansion plans are expected to increase revenues by approximately £33 million (US$55 million) over the coming 3 years, in line with previous guidance.
Europe: Gamma capacity in Europe is being increased across three facilities to accommodate new contract wins. In Ede (the Netherlands) the facility will be expanded by approximately 50%, in Radeberg (Germany) capacity will be increased by 30% and a new gamma pallet facility will be constructed in Bradford (UK) more than doubling capacity. In addition Synergy is extending its network of laboratories to Radeberg to provide microbiological, food and allergen testing services.
Asia: The Ethylene Oxide facility in Kuala Ketil (Malaysia) will receive a fourth 12 pallet chamber expanding capacity by 25%.
The Americas: Synergy will start construction on its sixth e-beam facility in the San Francisco North Bay area having secured contracts to underpin the new operation. This facility, targeted for completion April 2015, will augment two existing e-beams located in San Diego and provide customers with additional business continuity assurance. In addition, construction has started on a new laboratory in the existing San Diego facility. The previously announced additional e-beam in Saxonburg PA remains on schedule to commence operations March 2015.
"We are pleased to support the increasing demand from our multinational medical device customers for our sterilisation services. Following the construction of the e-beam in San Francisco, Synergy will have the largest global network of sterilisation facilities serving its customers across 15 countries in Europe, Asia, South Africa and the Americas," said Andrew McLean, CEO Applied Sterilization Technologies & Laboratories.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.